EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Advanced Accelerator Applications is currently pursuing marketing approval for
177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to
allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine
tumors, progressive under somatostatin analogue therapy to access the investigational
product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.